Danuglipron vs Lixisenatide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Danuglipron vs Lixisenatide: Lixisenatide has the stronger overall evidence (5 vs 3.5/10); they're alternatives for manage blood sugar — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Lixisenatide Edges Ahead

Lixisenatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Danuglipron0 wins

Lixisenatide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Dnu3.5

Danuglipron

Too few graded studiesLimited safety

Lix5.0

Lixisenatide

Too few graded studiesLimited safety

Evidence

Evidence Score

3.5/10

Studies: 12

Meta-analyses: 3

Level: Emerging

Evidence Score

Best5/10

Studies: 164

Meta-analyses: 55

Level: Moderate

Research findings

Verdict

Too few graded studies

Top outcomes

Glucose & glycemic controlToo few graded studies11
Weight & obesityToo few graded studies7
Safety & tolerabilityToo few graded studies1

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies134
Safety & adverse effectsToo few graded studies17
Weight managementToo few graded studies15

Shared outcomes (3)

Outcomes where both Danuglipron and Lixisenatide have evidence — compare verdict strength side-by-side.

Blood sugar & glycemic controlToo few graded studies11Too few graded studies134
Safety & adverse effectsToo few graded studies1Too few graded studies17
Weight managementToo few graded studies7Too few graded studies15

Dosage & timing

Recommended Dosage:

INVESTIGATIONAL — no approved consumer dose. In trials, danuglipron was dosed orally twice daily WITH food and escalated weekly to target doses (e.g. up to 120-200 mg BID); a modified-release once-daily form was later under evaluation. Not for self-administration; only appropriate within a clinical trial.

Warnings

INVESTIGATIONAL: danuglipron is NOT an approved medicine — it is a Pfizer drug in development with no long-term outcome data.
TROUBLED DEVELOPMENT: the twice-daily formulation was DISCONTINUED over GI tolerability, and a once-daily formulation was HALTED after a drug-induced liver-injury signal.
This is NOT a dietary supplement. It is an unapproved, prescription-class drug candidate.
GREY-MARKET RISK: never obtain danuglipron from research-chemical or grey-market vendors — off-trial product carries serious identity, dosing, purity, and liver-safety risks.
GLP-1-class gastrointestinal effects (nausea, vomiting, diarrhea) are VERY COMMON and dose-dependent — discontinuation ran far higher than placebo in every danuglipron trial.
Expected thyroid C-cell (medullary carcinoma) class warning — the GLP-1 class carries this concern.
NOT a longevity drug — there are no lifespan or healthspan data; evidence is early metabolic (HbA1c, weight) only.

Best Time:

Any time of day

Take with food

Best Form:

Oral tablet (investigational)

Recommended Dosage:

Prescription-only, clinician-directed. Subcutaneous 20 µg once daily within the hour before the first meal of the day, after a 10 µg starting dose for 14 days. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication (type 2 diabetes).
GLP-1 CLASS WARNING: thyroid C-cell tumors. GLP-1 receptor agonists cause thyroid C-cell (medullary) tumors in rodents; human relevance is undetermined. Avoid with a personal/family history of medullary thyroid carcinoma (MTC) or MEN2.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are common, especially during dose escalation.
Cardiovascular effect is NEUTRAL: the ELIXA trial showed no increase but ALSO no reduction in cardiovascular events — unlike liraglutide, semaglutide, and dulaglutide which have proven cardiovascular benefit.
Weight benefit is small — this is not a meaningful weight-loss agent.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).
Avoid COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved formulations. Use only pharmacy-dispensed product.
Largely superseded in practice by more potent once-weekly GLP-1 agonists.

Best Time:

Morning

Can take on empty stomach

Best Form:

Subcutaneous once-daily injection (Adlyxin / Lyxumia)

Safety

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrheaTreatment discontinuation due to GI events

Contraindications:

Not an approved medicine — only appropriate within a clinical trial
Hepatic-safety signal: a drug-induced liver-injury signal halted a once-daily formulation in development

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrheaSymptomatic hypoglycemia (mainly with insulin/sulfonylurea)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 class C-cell tumor warning
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Shared goals

Manage blood sugarLixisenatide

Danuglipron40/100

Lixisenatide50/100

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Weight losspositive

Months (titrated)

🤢 GI adverse effects (very common, dose-dependent, dropout-driving)trade-off

Especially during dose escalation

🫀 Hepatic safety signal / discontinued formstrade-off

Throughout / development-level

🩸 Modest glycemic controlpositive

Weeks (24-week endpoints)

🍽️ Strong postprandial glucose loweringpositive

Per meal / weeks

⚖️ Small / neutral weight effectneutral

Months

❤️ Neutral cardiovascular outcome (ELIXA)neutral

Median 25 months

Key studies

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial.

JAMA Netw Open (2023) · Rct · n=411

Phase-2b double-blind, placebo-controlled RCT (n=411) in adults with type 2 diabetes; twice-daily oral danuglipron 2.5/10/40/80/120 mg vs placebo over 16 weeks with weekly dose escalation

Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study.

Diabetes Obes Metab (2025) · Rct · n=628

Phase-2b double-blind, placebo-controlled, dose-ranging RCT (n=628) in adults with obesity WITHOUT diabetes; twice-daily oral danuglipron 40-200 mg over 26 or 32 weeks

Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.

Diabetes Obes Metab (2023) · Rct · n=151

Phase-2a double-blind, placebo-controlled RCT (n=151; T2D and obesity arms) comparing dose-escalation schemes of twice-daily danuglipron up to 200 mg BID over 12 weeks

All Danuglipron studies

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (ELIXA).

N Engl J Med (2015) · Rct · n=6068

Cardiovascular-outcomes RCT: 6,068 patients with type 2 diabetes and a recent acute coronary syndrome (MI or unstable angina within 180 days), lixisenatide vs placebo added to usual care, median 25 months

Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).

Diabetes Care (2012) · Rct · n=361

Phase-3 double-blind 12-week RCT, 361 drug-naive patients with type 2 diabetes randomized to lixisenatide (two titration regimens) or placebo

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).

Diabetes Care (2013) · Rct · n=495

Phase-3 double-blind RCT, 495 patients on established basal insulin with inadequate control, add-on lixisenatide 20 µg vs placebo for 24 weeks

All Lixisenatide studies

Frequently asked questions

Is Danuglipron better than Lixisenatide?

Lixisenatide has a higher evidence score (5/10 vs 3.5/10) and wins in 2 of 3 categories.

Is Danuglipron or Lixisenatide better for manage blood sugar?

For manage blood sugar, Lixisenatide has a higher relevance score (50 vs 40).

Can I take Danuglipron and Lixisenatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Iron vs Lixisenatide Lixisenatide vs Whey Protein Lixisenatide vs Semaglutide Lixisenatide vs Tirzepatide

Still deciding between Danuglipron and Lixisenatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Danuglipron details Lixisenatide details

Warnings

INVESTIGATIONAL: danuglipron is NOT an approved medicine — it is a Pfizer drug in development with no long-term outcome data.

TROUBLED DEVELOPMENT: the twice-daily formulation was DISCONTINUED over GI tolerability, and a once-daily formulation was HALTED after a drug-induced liver-injury signal.

This is NOT a dietary supplement. It is an unapproved, prescription-class drug candidate.

GREY-MARKET RISK: never obtain danuglipron from research-chemical or grey-market vendors — off-trial product carries serious identity, dosing, purity, and liver-safety risks.

GLP-1-class gastrointestinal effects (nausea, vomiting, diarrhea) are VERY COMMON and dose-dependent — discontinuation ran far higher than placebo in every danuglipron trial.

Expected thyroid C-cell (medullary carcinoma) class warning — the GLP-1 class carries this concern.

NOT a longevity drug — there are no lifespan or healthspan data; evidence is early metabolic (HbA1c, weight) only.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication (type 2 diabetes).

GLP-1 CLASS WARNING: thyroid C-cell tumors. GLP-1 receptor agonists cause thyroid C-cell (medullary) tumors in rodents; human relevance is undetermined. Avoid with a personal/family history of medullary thyroid carcinoma (MTC) or MEN2.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are common, especially during dose escalation.

Cardiovascular effect is NEUTRAL: the ELIXA trial showed no increase but ALSO no reduction in cardiovascular events — unlike liraglutide, semaglutide, and dulaglutide which have proven cardiovascular benefit.

Weight benefit is small — this is not a meaningful weight-loss agent.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Avoid COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved formulations. Use only pharmacy-dispensed product.

Largely superseded in practice by more potent once-weekly GLP-1 agonists.

Frequently asked questions

Is Danuglipron better than Lixisenatide?

Lixisenatide has a higher evidence score (5/10 vs 3.5/10) and wins in 2 of 3 categories.

Is Danuglipron or Lixisenatide better for manage blood sugar?

For manage blood sugar, Lixisenatide has a higher relevance score (50 vs 40).

Can I take Danuglipron and Lixisenatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.